• Profile
Close

Intraoperative dexamethasone reduces readmission rates but not venous thromboembolic events after lower extremity joint arthroplasty

Journal of Arthroplasty Jun 07, 2018

Klement MR, et al. - Experts evaluated the impact of perioperative dexamethasone on 90-day readmissions and the rates of clinically significant venous thromboembolic events (VTE) or readmission following total joint arthroplasty (TJA). The rate of clinically significant VTE and 90-day readmission were the primary outcomes. The secondary outcomes included wound complications, periprosthetic joint infection (PJI) and 90-day mortality. Findings did not suggest an association of a single, intraoperative, low-dose of dexamethasone with a reduction in clinically significant VTE but to lower 90-day readmission rates, it could be a safe and effective adjunct medication.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay